---
title: "Estimating COVID-19 bivalent booster VE with negative-control methods in a target-trial emulation"
id: "medrxiv-14-emulating-a-vaccine-target-trial-under-unmeasured-confounding-single-and-double"
canonical_url: "https://medichelpline.com/clinical-feed/medrxiv-14-emulating-a-vaccine-target-trial-under-unmeasured-confounding-single-and-double"
content_type: "clinical_feed_article"
specialty: "Infectious Disease"
source_name: "medRxiv (Clinical Preprints)"
source_url: "https://www.medrxiv.org/content/10.64898/2026.10.21.26366144v1?rss=1"
published_at: "2026-10-24T12:00:00.000Z"
evidence_level: "Verified Feed"
license: "CC-BY-NC-4.0 / Informational Use"
---
# Estimating COVID-19 bivalent booster VE with negative-control methods in a target-trial emulation
## Provenance & Clinical Metadata
- **Canonical URL:** https://medichelpline.com/clinical-feed/medrxiv-14-emulating-a-vaccine-target-trial-under-unmeasured-confounding-single-and-double
- **Specialty:** [Infectious Disease](https://medichelpline.com/clinical-feed/infectious-disease.md)
- **Primary Source:** medRxiv (Clinical Preprints)
- **Source URL:** [Original Journal Publication](https://www.medrxiv.org/content/10.64898/2026.10.21.26366144v1?rss=1)
- **Published At:** 2026-10-24T12:00:00.000Z
- **Evidence Rating:** Verified Feed
## Executive GIST (TL;DR)
- Investigators emulated a **target trial** to estimate relative **vaccine effectiveness** (VE) of the **COVID-19 bivalent booster** within a Kaiser Permanente Northern California cohort. - The study team observed residual unmeasured confounding tied to health-seeking behavior despite trial-emulation design efforts. - Authors reported use of negative controls: a single negative control outcome (test-negative illness) and a double negative control approach requiring an additional valid negative control. - One method assumes equi-confounding on the multiplicative scale and uses the test-negative illness to correct bias; the second relaxes that assumption but needs a second negative control. - The two negative-control approaches produced similar 1-year relative VE estimates (11.1% and 15.9%), while a traditional approach yielded a qualitatively different estimate (VE: -14.5%). - Data could not be publicly shared at the individual level because of protected health information; aggregate results are in the manuscript and analysis code is available on GitHub. - The authors noted ethical approvals from Kaiser Permanente Northern California IRB and declared no competing interests. - The report is a preprint and has not been peer reviewed; investigators cautioned against using these results to guide clinical practice.
## Clinical Analysis & Structured Key Points
Emulating a vaccine target trial under unmeasured confounding: single and double negative control methods | medRxiv Skip to main content Emulating a vaccine target trial under unmeasured confounding: single and double negative control methods View ORCID Profile Beau Schaeffer , Tyler Chervo , Eric P. Elkin , William P. Hanage , Joshua R. Nugent , Ilan N. Rubin , Joy Shi , Jacek Skarbinski , Christopher B. Boyer doi: https://doi.org/10.64898/2026.10.21.26366144 Beau Schaeffer 1 Center for Communicable Disease Dynamics, Department of Epidemiology, Harvard T.H. Chan School of Public Health, Boston, MA, USA; Find this author on Google Scholar Find this author on PubMed Search for this author on this site ORCID record for Beau Schaeffer For correspondence: beauschaeffer{at}g.harvard.edu Tyler Chervo 2 Division of Research, Kaiser Permanente Northern California, Pleasanton, CA, USA; Find this author on Google Scholar Find this author on PubMed Search for this author on this site Eric P. Elkin 2 Division of Research, Kaiser Permanente Northern California, Pleasanton, CA, USA; Find this author on Google Scholar Find this author on PubMed Search for this author on this site William P. Hanage 1 Center for Communicable Disease Dynamics, Department of Epidemiology, Harvard T.H. Chan School of Public Health, Boston, MA, USA; Find this author on Google Scholar Find this author on PubMed Search for this author on this site Joshua R. Nugent 2 Division of Research, Kaiser Permanente Northern California, Pleasanton, CA, USA; Find this author on Google Scholar Find this author on PubMed Search for this author on this site Ilan N. Rubin 1 Center for Communicable Disease Dynamics, Department of Epidemiology, Harvard T.H. Chan School of Public Health, Boston, MA, USA; Find this author on Google Scholar Find this author on PubMed Search for this author on this site Joy Shi 3 CAUSALab, Department of Epidemiology, Harvard T.H. Chan School of Public Health, Boston, MA, USA; Find this author on Google Scholar Find this author on PubMed Search for this author on this site Jacek Skarbinski 2 Division of Research, Kaiser Permanente Northern California, Pleasanton, CA, USA; Find this author on Google Scholar Find this author on PubMed Search for this author on this site Christopher B. Boyer 4 Department of Medicine, Cleveland Clinic Lerner College of Medicine of Case Western University, Cleveland, OH, USA Find this author on Google Scholar Find this author on PubMed Search for this author on this site Abstract Info/History Metrics Data/Code Preview PDF Abstract Estimating vaccine effectiveness (VE) for symptom-driven outcomes in observational settings remains challenging due to unmeasured differences in health-seeking behavior between vaccine groups. This challenge persists even with target trial emulation, which primarily addresses design-related biases. The test negative design, a popular alternative design for estimating VE, can reduce bias due to unmeasured confounding by health-seeking but often deviates from the design principles of trial emulation. Here, we emulate a target trial to estimate relative VE of COVID-19 bivalent booster in a cohort of Kaiser Permanente of Northern California members and provide evidence for residual unmeasured confounding through negative controls. We then propose two approaches for estimating VE that operate within the target trial framework but allow for unmeasured confounding. The first uses test-negative illness as a negative control outcome and corrects for bias under the assumption of equi-confounding on the multiplicative scale. The second relaxes equi-confounding but requires an additional (valid) negative control. The two approaches yield similar estimates of 1-year relative VE (11.1% vs. 15.9%) but are both qualitatively different from traditional methods (VE: -14.5%). These approaches illustrate the flexibility of the target trial framework which can retain sound design principles while accommodating alternative identification strategies. Competing Interest Statement The authors have declared no competing interest. Author Declarations I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained. Yes The details of the IRB/oversight body that provided approval or exemption for the research described are given below: Kaiser Permanente of Northern California IRB gave ethical approval for this work I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals. Yes I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance). Yes I have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable. Yes Data Availability The individual-level electronic health record data analyzed in this study contain protected health information and cannot be shared publicly, in accordance with institutional policies and data use agreements with Kaiser Permanente Northern California. Aggregate results supporting the findings are contained in the manuscript. Analysis code is available at https://github.com/BeauSchaeffer/tte-tnd Funder Information Declared National Institutes of Health, https://ror.org/01cwqze88 , T32AI007535 Copyright The copyright holder for this preprint is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a CC-BY-NC-ND 4.0 International license . Back to top Previous Next Posted October 24, 2026. Download PDF Data/Code Email Thank you for your interest in spreading the word about medRxiv. NOTE: Your email address is requested solely to identify you as the sender of this article. Your Email * Your Name * Send To * Enter multiple addresses on separate lines or separate them with commas. You are going to email the following Emulating a vaccine target trial under unmeasured confounding: single and double negative control methods Message Subject (Your Name) has forwarded a page to you from medRxiv Message Body (Your Name) thought you would like to see this page from the medRxiv website. Your Personal Message CAPTCHA This question is for testing whether or not you are a human visitor and to prevent automated spam submissions. Share Emulating a vaccine target trial under unmeasured confounding: single and double negative control methods Beau Schaeffer , Tyler Chervo , Eric P. Elkin , William P. Hanage , Joshua R. Nugent , Ilan N. Rubin , Joy Shi , Jacek Skarbinski , Christopher B. Boyer medRxiv 2026.10.21.26366144; doi: https://doi.org/10.64898/2026.10.21.26366144 Share This Article: Copy Citation Tools Emulating a vaccine target trial under unmeasured confounding: single and double negative control methods Beau Schaeffer , Tyler Chervo , Eric P. Elkin , William P. Hanage , Joshua R. Nugent , Ilan N. Rubin , Joy Shi , Jacek Skarbinski , Christopher B. Boyer medRxiv 2026.10.21.26366144; doi: https://doi.org/10.64898/2026.10.21.26366144 Citation Manager Formats BibTeX Bookends EasyBib EndNote (tagged) EndNote 8 (xml) Medlars Mendeley Papers RefWorks Tagged Ref Manager RIS Zotero Tweet Widget Facebook Like Google Plus One Subject Areas All Articles Addiction Medicine (634) Allergy and Immunology (914) Anesthesia (348) Cardiovascular Medicine (4947) Dentistry and Oral Medicine (490) Dermatology (425) Emergency Medicine (674) Endocrinology (including Diabetes Mellitus and Metabolic Disease) (1670) Epidemiology (16171) Forensic Medicine (36) Gastroenterology (1236) Genetic and Genomic Medicine (7216) Geriatric Medicine (747) Health Economics (1092) Health Informatics (5229) Health Policy (1457) Health Systems and Quality Improvement (1815) Hematology (597) HIV/AIDS (1373) Infectious Diseases (except HIV/AIDS) (16431) Intensive Care and Critical Care Medicine (1193) Medical Education (692) Medical Ethics (156) Nephrology (739) Neurology (7509) Nursing (375) Nutrition (1114) Obstetrics and Gynecology (1286) Occupational and Environmental Health (1032) Oncology (3711) Ophthalmology (1081) Orthopedics (401) Otolaryngology (462) Pain Medicine (494) Palliative Medicine (142) Pathology (717) Pediatrics (1846) Pharmacology and Therapeutics (749) Primary Care Research (781) Psychiatry and Clinical Psychology (6068) Public and Global Health (9925) Radiology and Imaging (2501) Rehabilitation Medicine and Physical Therapy (1501) Respiratory Medicine (1263) Rheumatology (656) Sexual and Reproductive Health (795) Sports Medicine (594) Surgery (796) Toxicology (109) Transplantation (315) Urology (303)
## Related Clinical Research

- [Remembering Helen Branswell — STAT’s Infectious-Disease Reporter](https://medichelpline.com/clinical-feed/stat-news-3-remembering-stat-s-helen-branswell.md)
- [NG-TEST Acineto-5 accurately detects OXA, NDM, and VIM carbapenemases in Acinetobacter spp.](https://medichelpline.com/clinical-feed/medrxiv-5-validation-of-ng-test-acineto-5-for-the-detection-of-oxa-carbapenemases-ndm-and.md)
- [Patient accounts from Nairobi show fear-driven distancing in COVID-19 isolation care](https://medichelpline.com/clinical-feed/medrxiv-2-they-could-just-come-they-peep-then-they-get-back-covid-19-patients-experiences.md)
- [GSK wins approval for hepatitis B therapy as biotech news ripples through sector](https://medichelpline.com/clinical-feed/stat-news-0-stat-gsk-picks-up-hep-b-drug-approval.md)
- [HPV mRNA vaccine candidate — article content not available for clinical details](https://medichelpline.com/clinical-feed/frontiers-in-immunology-17-a-novel-hpv-mrna-vaccine-candidate-immunogenicity-and-definition-of-immune.md)

## Navigation
- [← Back to Infectious Disease Feed](https://medichelpline.com/clinical-feed/infectious-disease.md)
- [← All Clinical Specialties](https://medichelpline.com/clinical-feed.md)
## Medical & Regulatory Disclaimer

> [!CAUTION]
> MedicHelpline content is structured for research, educational, and professional discovery purposes. It does not constitute individual medical advice, clinical diagnosis, or treatment recommendations.
> Always verify dosing, contraindications, and regulatory alerts against official product labeling and primary regulatory sources before clinical decision-making.